Wu, Katherine http://orcid.org/0000-0002-0472-0166
El Zowalaty, Ahmed Ezat http://orcid.org/0000-0001-6177-6142
Sayin, Volkan I. http://orcid.org/0000-0002-5225-8260
Papagiannakopoulos, Thales http://orcid.org/0000-0002-2251-1624
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R37CA222504, R01CA227649)
American Cancer Society (RSG-17-200-01–TBE)
Emerald Foundation Young Investigator Award
U.S. Department of Health & Human Services | National Institutes of Health (T32GM136573, F30CA275258)
Vetenskapsrådet (S18-034)
Cancerfonden (20-1278)
Article History
Received: 14 March 2022
Accepted: 19 January 2024
First Online: 22 March 2024
Competing interests
: V.I.S. consults for Pretzel Therapeutics. T.P. reports grants from Dracen Pharmaceuticals, grants from Kymera Therapeutics, grants from Bristol Myers Squibb, grants from Agios Pharmaceuticals, personal fees from Vividion Therapeutics, personal fees from Tohoku University and personal fees from Faeth Therapeutics outside the submitted work. In addition, T.P. has a patent for US-20210361603-A1 pending and a patent for US-20210085763-A1 pending. K.W. and A.E.E.Z. declare no competing interests.